Navigation Links
Research shows biopsy of recurrent breast cancer can alter treatment
Date:3/18/2009

(Toronto March 18, 2009) For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer. A group from Toronto has recently completed the world's first study that compared original breast cancer tumors with a biopsy of suspected tumors that recurred elsewhere in the body.

Researchers found that the biopsy resulted in 20% of the women having a significant change in their treatment. In some cases, this was a change in drug treatment and in others, the biopsy showed the woman did not actually have an advanced cancer, but a benign condition.

"The results show that cancers may change over time and not respond to treatment that was appropriate for the original cancer," says principal investigator Dr. Mark Clemons, a medical oncologist specializing in breast cancer in the Princess Margaret Hospital Cancer Program, University Health Network (UHN).

"These early findings are leading us in a new direction as we understand more about why some women don't respond to treatment. This knowledge will help us in our quest to always deliver the right treatment, to the right patient, at the right time."

The findings are published online today in the Annals of Oncology, Oxford University Press (Doi:10.1093/annonc/mdp028).

Dr. Clemons's study -- funded by a $100,000 research grant from the Canadian Breast Cancer Foundation - Ontario Region -- evaluated 29 biopsies of accessible, recurrent tumors taken from women whose breast cancer had spread to bone, skin, lymph nodes, lung or liver.

Pathologists compared the results of the original cancer with the results of the new biopsy by analyzing the predictive markers that influence breast cancer tumor growth estrogen, progesterone and Her2 status. The presence, absence and/or combinations of these markers become the map oncologists use to determine the most effective treatment for each patient.<
'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Georgia State/Georgia Tech Center for Advanced Brain Imaging to expand brain, mind research
2. Conflicts of interest in clinical research
3. Stimulus Spending Targets Modernization of the Nation's Research Infrastructure
4. Researchers Use Gene to End High Blood Sugar in Mice
5. Major Asthma Research Discovery Could Lead to New Drugs
6. Penn researchers identify new protein important in breast cancer genes role in DNA repair
7. New research suggests common anti-seizure medications may increase risk of cardiovascular problems
8. Researcher wins $2.6 million grant for depression care study
9. Frost and Sullivan Picks Epinex for Diabetes Research Award
10. Foundation for Biomedical Research Releases Groundbreaking PSA
11. Fish health claims may cause more environmental harm than good: UBC-St. Michaels researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Mercy Gynecologic Oncologist Dr. Dwight Im Receives &#8220;Patients' Choice&#8221; Award 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 2Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 3Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 4Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 2Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 3Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 4Health News:Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases 2
Other Medicine News:Health News:Post-Debate Statement From AARP Spokesperson Drew Nannis 2Health News:Black Caribbeans do better in America than in England 2Health News:Black Caribbeans do better in America than in England 3Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 2Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 3Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 4Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 5Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 6Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 7Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 8Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 9Health News:Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance 10Health News:AIDS Action Committee Testifies to Protect the Privacy of People Seeking Healthcare in Massachusetts 2
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Ohio Nurses Association Announces New President 3B 2009 2011 Board of Directors 61172 1Ohio Nurses Association Announces New President 3B 2009 2011 Board of Directors 61172 2Ingenious Med Partners with Childrens Restoration Network for Holiday Charity 61170 1Ingenious Med Partners with Childrens Restoration Network for Holiday Charity 61170 2Cellerix Raises EUR27 Million in a First Closing 14796 1Cellerix Raises EUR27 Million in a First Closing 14796 2